EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, CARISMA Therapeutics's enterprise value is $9.14 Mil.
CARISMA Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $15.07 Mil. Therefore, CARISMA Therapeutics's EV-to-Revenue for today is 0.61.
The historical rank and industry rank for CARISMA Therapeutics's EV-to-Revenue or its related term are showing as below:
CARM'
s EV-to-Revenue Range Over the Past 10 Years
Min: -7.94 Med: 1.3 Max: 20.61
Current: 0.61
During the past 4 years, the highest EV-to-Revenue of CARISMA Therapeutics was 20.61. The lowest was -7.94. And the median was 1.30.
CARM's EV-to-Revenue is ranked better than 89.63% of 1041
companies
in the Biotechnology industry
Industry Median: 8.07
vs CARM: 0.61
CARISMA Therapeutics EV-to-Revenue Historical Data
The historical data trend for CARISMA Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CARISMA Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, CARISMA Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CARISMA Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where CARISMA Therapeutics's EV-to-Revenue falls into.
CARISMA Therapeutics's current Enterprise Value is $9.14 Mil.
CARISMA Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CARISMA Therapeutics's share price for today is $1.38.
CARISMA Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.37.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CARISMA Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of CARISMA Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
CARISMA Therapeutics (CARISMA Therapeutics) Business Description
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CARM has been successfully added to your 